Our top pick for
Building a portfolio
Neovasc Inc is a medical devices business based in the US. Neovasc shares (NVCN) are listed on the NASDAQ and all prices are listed in US Dollars. Neovasc employs 110 staff and has a trailing 12-month revenue of around USD$2 million.
|52-week range||USD$0.71 - USD$3.38|
|50-day moving average||USD$1.5057|
|200-day moving average||USD$1.4969|
|Wall St. target price||USD$1.88|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-5.638|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Neovasc stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Neovasc's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Neovasc's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 0x. In other words, Neovasc shares trade at around 0x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||USD$2 million|
|Gross profit TTM||USD$1.6 million|
|Return on assets TTM||-130.67%|
|Return on equity TTM||0%|
|Market capitalisation||USD$82.8 million|
TTM: trailing 12 months
There are currently 2.0 million Neovasc shares held short by investors – that's known as Neovasc's "short interest". This figure is 82.6% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting Neovasc shares can be evaluated.
Neovasc's "short interest ratio" (SIR) is the quantity of Neovasc shares currently shorted divided by the average quantity of Neovasc shares traded daily (recently around 16.5 million). Neovasc's SIR currently stands at 0.12. In other words for every 100,000 Neovasc shares traded daily on the market, roughly 120 shares are currently held short.
However Neovasc's short interest can also be evaluated against the total number of Neovasc shares, or, against the total number of tradable Neovasc shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Neovasc's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Neovasc shares in existence, roughly 20 shares are currently held short) or 0.0165% of the tradable shares (for every 100,000 tradable Neovasc shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Neovasc.
Find out more about how you can short Neovasc stock.
We're not expecting Neovasc to pay a dividend over the next 12 months.
Neovasc's shares were split on a 1:10 basis on 1 July 2019. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Neovasc shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Neovasc shares which in turn could have impacted Neovasc's share price.
Over the last 12 months, Neovasc's shares have ranged in value from as little as $0.71 up to $3.38. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Neovasc's is 2.9086. This would suggest that Neovasc's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets medical devices for cardiovascular marketplace in Europe, the United States, and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.
Steps to owning and managing SGLB, with 24-hour and historical pricing before you buy.
Steps to owning and managing SSD, with 24-hour and historical pricing before you buy.
Steps to owning and managing SQNS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFL, with 24-hour and historical pricing before you buy.
Steps to owning and managing AIHS, with 24-hour and historical pricing before you buy.
Steps to owning and managing ST, with 24-hour and historical pricing before you buy.
Steps to owning and managing SLCT, with 24-hour and historical pricing before you buy.
Steps to owning and managing EYES, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBSW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SHG, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.